anim
product
industri
profitdirect
busi
goal
anim
produc
rais
healthi
finish
anim
correct
weight
market
costeffect
manner
shortest
possibl
time
cost
produc
anim
includ
initi
obtain
feed
achiev
maximum
feed
convers
averag
daili
weight
gain
keep
healthi
protect
diseas
obvious
health
anim
significantli
affect
product
produc
must
also
ensur
breed
stock
produc
healthi
offspr
often
natur
permit
interven
possibl
increas
product
beyond
natur
limit
biotechnolog
aid
help
improv
anim
health
feed
convers
shorten
time
anim
achiev
market
weight
worth
consider
cost
aid
must
howev
weigh
improv
product
provid
biotechnolog
aid
appli
mani
area
includ
mechan
increas
success
pregnanc
hormon
artifici
insemin
oestruspregn
detect
test
diseas
monitor
vaccin
pregnant
anim
protect
offspr
diseas
diseas
monitor
vaccin
neonat
offspr
prophylact
antibiot
supplement
feed
continu
protect
growth
promot
maxim
feed
convers
ratio
biotechnolog
form
murin
hybridoma
monoclon
antibodi
mab
use
numer
research
applic
ultim
benefit
anim
produc
area
mani
review
author
booman
nielsen
et
al
snyder
mccullough
et
al
van
brunt
practic
applic
directli
affect
industri
howev
includ
follow
mabbas
immunoassay
monitor
ovul
detect
pregnanc
cattl
booman
et
al
sever
kit
commerci
avail
includ
calfcheck
heifercheck
calfcheck
confirm
american
diagnost
sale
westport
ct
van
brunt
ii
mabbas
rapid
immunodiagnost
assay
earli
identif
diseas
outbreak
enabl
isol
infect
anim
reduc
spread
diseas
iii
mab
specif
infecti
agent
use
either
directli
passiv
immun
indirectli
immunopurif
protect
antigen
activ
immun
infecti
diseas
rang
anim
speci
iv
mab
use
therapeut
modifi
specif
physiolog
function
increas
anim
product
eg
increas
frequenc
ovul
growth
promotor
v
mab
immunoglobulin
specif
cell
surfac
marker
potenti
apphcat
immunodiagnosi
immunotherapi
sever
diseas
state
certain
type
tumour
research
applic
mab
discuss
chapter
focu
applic
mab
directli
benefit
anim
health
product
industri
method
product
cultur
mabsecret
hybridoma
screen
cultur
supernat
presenc
specif
mab
purif
select
mab
cultur
supernat
ascit
fluid
review
detail
elsewher
repeat
nielsen
et
al
fuller
et
al
two
import
cautionari
point
howev
mention
emphas
appropri
place
later
chapter
attempt
produc
mab
research
absolut
sure
intend
applic
assay
system
determin
suitabihti
mab
intend
apphcat
develop
optim
use
test
cultur
supernat
earli
possibl
hybridoma
product
process
mani
research
screen
hybridoma
cultur
supernat
use
microtitr
elisa
system
though
microtitr
elisa
simpl
conveni
screen
method
detect
mab
bind
target
antigen
coat
microtitr
plate
owe
uniqu
specif
properti
mab
detect
way
may
suitabl
use
applic
may
exampl
react
nativ
antigen
immunohistopatholog
immunocytochemistri
antigen
solut
sandwich
captur
elisa
irrevers
bind
antigen
act
immunoadsorb
exampl
phenomenon
describ
thiriart
et
al
difficulti
obtain
neutral
mab
bovin
rotaviru
use
elisa
system
screen
hybridoma
supernat
group
therefor
develop
rapid
sensit
rotaviru
neutral
assay
adopt
direct
screen
primari
hybridoma
supernat
use
assay
obtain
neutral
mab
one
fusion
gave
neg
result
test
origin
elisa
detect
rotaviru
antibodi
ii
method
product
techniqu
requir
level
purif
mab
depend
intend
applic
research
produc
mab
ascit
cultur
mice
vitro
product
method
howev
rapidli
becom
cost
effici
addit
purif
mab
ascit
fluid
contain
high
level
contamin
host
mous
immunoglobulin
often
complex
therefor
costli
purif
cultur
supernat
contain
low
concentr
serum
requir
degre
puriti
must
determin
basi
intend
applic
exampl
high
puriti
mab
necessari
immunotherapi
inject
ascit
fluid
contain
specif
mab
may
suitabl
immunotherapi
oral
administr
see
section
temptat
overpurifi
mab
avoid
minim
unnecessari
cost
specif
activ
select
mab
activ
per
mg
protein
prepar
monitor
ensur
increas
step
purif
scheme
applic
monoclon
antibodi
mab
anim
health
product
may
conveni
divid
four
area
immunocharacter
immunopurif
immunocharacter
immunopurif
immunoassay
immunotherapi
interrelationship
four
main
area
applic
monoclon
antibodi
anim
health
product
applic
indic
broken
line
arrow
util
monoclon
antibodi
applic
indic
solid
line
arrow
util
immunoaffin
purifi
antigen
immunoassay
immunotherapi
four
area
howev
exclus
one
anoth
fact
mutual
interconnect
way
shown
figur
immunocharacter
involv
character
mab
specif
characteriz
ation
mab
might
involv
ascertain
isotyp
affin
constant
biolog
activ
may
presenc
target
antigen
instanc
neutral
case
viru
complement
fixat
agglutin
character
mab
specif
yield
valuabl
inform
structur
target
antigen
use
exampl
western
blot
polyacrylamid
gel
electrophoresi
immun
precipit
comparison
mab
biolog
properti
also
identifi
function
antigen
e
g
neutral
haemagglutin
epitop
antigen
involv
function
epitop
map
elucid
true
natur
epitop
sela
aid
use
mab
van
regenmortel
complet
immunocharacteriz
ation
perform
appli
mab
intend
purpos
character
mab
specif
perform
next
area
consider
depend
whether
desir
apphcat
involv
mab
antigen
immunoaffin
purifi
use
mab
figur
true
regardless
whether
intend
use
immunoassay
immunotherapi
mab
use
applic
indic
broken
line
arrow
figur
would
pursu
immedi
antigen
mab
direct
util
immunopurif
step
requir
necessit
immobil
mab
suitabl
solid
phase
normal
gel
matrix
intent
chapter
advis
choic
solid
phase
matrix
suitabl
may
vari
depend
mab
target
antigen
purifi
cnbractiv
agaros
may
suitabl
system
whilst
other
may
requir
chemic
substitut
gel
spacer
arm
stress
mab
suitabl
use
solid
phase
immunoadsorb
mab
must
evalu
suitabiuti
intend
use
earli
possibl
product
choic
eluent
affin
purif
antigen
compon
use
mab
immunoadsorb
ent
must
care
consid
mab
target
antigen
denatur
exposur
commonli
use
eluent
lead
research
conclud
mab
suitabl
immunopurif
individu
treatment
crude
antigen
prepar
mab
work
concentr
variou
elut
agent
prior
applic
solid
phase
immunoadsorb
matrix
follow
test
treat
crude
antigen
mab
ascertain
whether
immunolog
reactiv
reduc
avoid
wast
time
effort
immunoassay
fall
two
area
depend
whether
mab
use
antigen
detect
whether
antigen
affin
purifi
use
mab
solid
phase
immunoadsorb
use
antibodi
detect
applic
may
involv
sever
differ
techniqu
former
includ
immunohistopatholog
immunocytochemistri
particl
agglutin
particl
coat
mab
immunoradiometr
assay
radioimmunoassay
sandwich
elisa
competit
inhibit
elisa
latter
applic
includ
particl
agglutin
particl
coat
antigen
complement
fixat
elisa
competit
inhibit
elisa
excel
descript
techniqu
publish
elsewher
nielsen
et
al
winston
et
al
therefor
duplic
previou
caution
howev
repeat
everi
mab
suitabl
use
immunoassay
techniqu
thu
care
screen
mab
suitabl
intend
purpos
perform
earli
possibl
product
caution
equal
applic
area
immunotherapi
describ
next
paragraph
immunotherapi
use
mab
defin
purpos
chapter
compris
three
area
use
antigen
nativ
recombin
affin
purifi
use
mab
solid
phase
immunoadsorb
activ
immun
diseas
ii
use
antiidiotyp
mab
antigen
structur
parasit
seem
complex
compar
rel
simplic
mani
infecti
agent
complex
present
uniqu
challeng
use
mab
character
control
parasit
infect
sever
anim
health
product
emphas
need
appli
everi
avail
biotechnolog
tool
field
much
knowledg
gain
research
area
anim
health
may
directli
applic
control
similar
diseas
human
applic
mab
parasit
diseas
review
respect
diagnosi
gambl
vaccin
develop
gambl
zarlenga
gambl
howev
two
public
field
noteworthi
illustr
relationship
mab
applic
shown
solid
fine
arrow
figur
graham
produc
mab
immunocharacter
trichinella
spirali
antigen
use
select
mab
immunoaffin
purifi
stichocyt
antigen
trichinellaspecif
antigen
util
elisa
test
swine
sera
complet
elimin
fals
posit
reaction
caus
presenc
sera
crossreact
antibodi
parasit
identifi
pig
infect
trichinosi
wright
etal
also
use
mab
character
antigen
babesia
bovi
employ
select
mab
immunoaffin
purifi
b
bovi
antigen
author
went
demonstr
activ
immun
one
immunoaffin
purifi
antigen
protect
suscept
calv
challeng
virul
b
bovi
mab
also
employ
antigen
character
detect
trypanosoma
cruzi
arauio
etal
fasciola
hanna
trudgett
theileria
sergenti
kobayashi
etal
field
neonat
diarrhoea
research
mab
made
greatest
contribut
anim
health
mab
technolog
appli
major
pathogen
caus
scour
neonat
calv
piglet
lamb
greenberg
et
al
demonstr
mab
major
structur
protein
rotaviru
could
use
preliminari
serotyp
strain
differ
anim
speci
sabara
et
al
use
mab
map
epitop
glycoprotein
involv
neutral
bovin
rotaviru
viru
attach
cell
infect
sonza
et
al
thiriart
et
al
also
produc
neutral
mab
rotaviru
whilst
direct
detect
rotaviru
porcin
faecal
specimen
achiev
liprandi
et
al
use
mab
kda
group
specif
antigen
doubl
sandwich
indirect
elisa
system
develop
mab
sandwich
captur
elisa
system
direct
detect
bovin
enter
coronaviru
bec
faecal
specimen
scour
calv
report
modifi
elisa
system
demonstr
shed
coronaviru
rotaviru
faec
clinic
normal
cow
either
free
viral
antigen
viral
antigenbovin
immunoglobulin
complex
data
suggest
subclin
infect
cow
rotaviru
coronaviru
common
possibl
provid
sourc
infect
neonat
elisa
system
type
could
provid
import
epidemiolog
inform
enter
viru
infect
suggest
mean
improv
manag
neonat
diarrhoea
outbreak
research
also
activ
immun
diseas
iii
use
mab
specif
epitop
infecti
agent
cell
surfac
antigen
biolog
activ
molecul
eg
hormon
either
conjug
effector
molecul
passiv
immun
infecti
diseas
tumour
immunomodul
immunoregul
immun
endocrin
system
note
mab
requir
immunocharacter
use
applic
immunopurif
necessari
affin
purifi
antigen
use
therefor
remaind
chapter
rather
consid
four
area
defin
figur
individu
applic
mab
anim
health
product
discuss
two
head
immunoassay
immunotherapi
divid
appropri
subsect
field
viral
induc
respiratori
diseas
two
pubhcat
noteworthi
identifi
viral
antigen
may
import
protect
diseas
report
describ
use
select
mab
character
function
certain
glycoprotein
antigen
bovin
herp
viru
infecti
bovin
rhinotrach
viru
van
drunen
littelvan
den
hurk
babiuk
use
mab
identifi
glycoprotein
respons
viru
neutral
complement
depend
lysi
viru
infect
cell
went
map
epitop
two
glycoprotein
involv
function
author
demonstr
combin
mab
synergist
effect
viru
neutral
show
one
epitop
involv
biolog
properti
chang
et
al
also
use
mab
demonstr
glycoprotein
involv
viru
neutral
unfortun
differ
nomenclatur
assign
two
group
prevent
direct
comparison
data
though
mab
assist
understand
yet
fulfil
expect
respiratori
bacteria
infect
cattl
sheep
swine
mab
pasteurella
haemolytica
infecti
agent
implic
ship
fever
syndrom
calv
cytotoxin
pasteurella
multocida
haemophilu
pleuropneumonia
bordetella
bronchiseptica
respiratori
mycoplasma
speci
date
contribut
significantli
solv
problem
associ
accur
diagnosi
success
therapi
bacteri
respiratori
pathogen
foodproduc
anim
one
diseas
confound
anim
produc
research
mani
year
bovin
brucellosi
nation
scheme
erad
bovin
brucellosi
place
year
us
year
canada
year
variou
countri
erad
scheme
involv
vaccin
cattl
follow
serodiagnost
test
slaughter
anim
give
posit
test
result
success
mani
erad
scheme
thwart
inabl
serodiagnost
test
employ
discrimin
antibodi
titr
result
activ
infect
brucella
abortu
residu
antibodi
titr
remain
result
vaccin
diseas
countless
year
research
improv
serodiagnost
test
bovin
brucellosi
culmin
advent
mab
technolog
earliest
public
area
report
product
mab
b
abortu
surfac
antigen
holman
et
al
quinn
et
al
schurig
et
al
though
author
discuss
potenti
applic
mab
serodiagnosi
bovin
brucellosi
bundl
etal
employ
util
becspecif
mab
show
kda
structur
polypeptid
bec
volv
viru
neutral
haemagglutin
reaction
c
f
crouch
person
commun
mab
transmiss
gastroenter
coronaviru
swine
use
defin
antigen
structur
laud
et
al
rapid
diagnosi
jenkin
et
al
also
employ
monoclon
antibodi
diagnost
tool
swine
diarrhoea
case
swine
dysenteri
caus
spirochaet
treponema
hyodysenteria
mab
use
extens
studi
enterotoxigen
escherichia
coli
etec
caus
neonat
diarrhoea
calv
piglet
rapid
specif
mab
competit
elisa
detect
e
coli
heatstabl
enterotoxin
cultur
supernat
develop
thompson
et
al
author
util
mab
studi
fimbria
pilu
antigen
etec
involv
adhes
bacteri
cell
line
small
intestin
foge
et
al
demonstr
differ
serotyp
fimbria
schifferii
et
al
use
mab
probe
subunit
polymerspecif
epitop
fimbria
morri
et
al
investig
presenc
fimbria
etec
calv
piglet
lamb
mab
bacteri
agglutin
test
mill
tietz
employ
anoth
mab
sandwich
elisa
identifi
etec
cultur
isol
calv
direct
detect
etec
fimbrial
antigen
faecal
specimen
would
advantag
avoid
necess
cultur
mab
elisa
directli
detect
fimbrial
antigen
swine
faecal
specimen
describ
mill
et
al
direct
detect
bovin
faec
holley
et
al
direct
detect
quantit
fimbrial
antigen
bovin
faec
raybould
et
al
mani
group
produc
mab
infecti
agent
use
either
immunocharacter
immunodiagnosi
signific
advanc
knowledg
structur
epidemiolog
detect
sever
import
virus
achiev
use
mab
mab
rabi
viru
employ
molecular
analysi
natur
antigen
variant
flamand
et
al
koprowski
wiktor
rupprecht
et
al
distinguish
street
vaccin
laboratori
strain
smith
et
ai
antigen
character
street
viru
strain
toui
et
al
mab
footandmouth
diseas
viru
enabl
antigen
character
epitop
map
mccuuough
butcher
robertson
et
al
product
mab
major
core
protein
maedivisna
viru
enabl
develop
onestep
competit
elisa
detect
serum
antibodi
ovin
caprin
lentivirus
houwer
schaak
character
scrapi
prion
protein
also
attempt
use
mab
barr
prusin
use
mab
bovin
viral
diarrhoea
viru
immunofluoresc
antibodi
techniqu
aid
preliminari
serolog
character
strain
peter
et
al
indirect
competit
elisa
system
utihz
mab
detect
antibodi
viru
bovin
sera
juntti
et
al
mab
swine
fever
viru
enabl
develop
elisa
immunocytochemistri
system
routin
differenti
diagnosi
swine
fever
viru
infect
vaccin
bovin
viral
diarrhoea
infect
wensvoort
et
al
mab
bluetongu
viru
use
analysi
serotyp
restrict
unrestrict
viral
antigen
determin
detect
viru
groupspecif
antibodi
cattl
sheep
mabblock
competit
elisa
anderson
anderson
demonstr
viral
antigen
infect
tissu
cherrington
et
al
bovin
leukemia
leukosi
viru
blv
infect
cattl
anoth
area
elisa
system
enabl
detect
virusspecif
serum
antibodi
portetel
et
al
mammerickx
et
al
portetel
et
al
portetel
et
al
author
util
mab
glycoprotein
whilst
logan
et
al
develop
mab
probabl
envelop
glycoprotein
studi
yoneda
et
al
attempt
blv
antigen
detect
use
blvspecif
mab
colorimetr
cytotox
assay
detect
tumourassoci
antigen
blv
infect
cell
peripher
blood
sampl
leukem
cattl
mab
confirm
serolog
crossreact
lp
oantigen
b
abortu
yersinia
enterocolitica
type
first
report
ahvonen
et
al
confirm
diaz
jone
first
report
describ
use
ab
attempt
improv
serodiagnosi
brucellosi
gorrel
et
al
author
use
mab
rais
virul
strain
b
abortu
elisa
detect
antibodi
virul
b
abortu
elisa
howev
discrimin
sera
infect
vaccin
cattl
better
exist
serodiagnost
test
sutherland
incorpor
pair
mab
b
abortu
competit
elisa
fail
obtain
improv
discrimin
compar
exist
serodiagnost
test
bundesen
et
al
produc
panel
mab
b
abortu
cell
surfac
antigen
two
distinct
set
characterist
one
group
mab
agglutin
bacteri
cell
react
solubl
prepar
lipopolysaccharid
second
group
mab
capabl
agglutin
bacteri
cell
bind
solubl
lipopolysaccharid
react
elisa
system
antigen
present
ultrason
brucella
cell
two
mab
actual
exhibit
differenti
reactiv
ultrason
virul
nonvirul
strain
b
abortu
therefor
show
potenti
improv
serodiagnost
test
author
select
mab
group
describ
previou
paper
agglutin
bacteria
react
solubl
prepar
lipopolysaccharid
prepar
horseradish
peroxidas
conjug
use
competit
elisa
system
screen
bovin
sera
competit
elisa
system
improv
discrimin
sera
infect
vaccin
cattl
compar
exist
serodiagnost
test
sutherland
holland
similarli
compar
abil
competit
elisa
describ
sutherland
paper
exist
serodiagnost
test
complement
fixat
test
conclud
competit
elisa
also
enabl
improv
discrimin
infect
vaccin
anim
anoth
peroxidaselabel
mab
elisa
recent
describ
hen
et
al
hope
cumul
effort
differ
group
use
mab
enabl
achiev
goal
absolut
discrimin
anim
infect
brucellosi
vaccin
diseas
mab
produc
varieti
mediat
anim
immun
respons
includ
immunoglobuun
immun
cell
surfac
marker
mab
immunoglobuhn
use
three
main
applic
character
map
epitop
involv
variou
immunoglobuun
function
ii
quantit
level
differ
immunoglobulin
class
subclass
guid
immun
statu
anim
iii
quantit
differenti
respons
immunoglobuun
class
subclass
specif
infecti
agent
use
mab
first
apphcat
map
sheep
igg
igg
subclass
describ
beh
first
two
applic
allud
variou
group
produc
mab
bovin
iggi
fleenor
et
al
bovin
srikumaran
et
al
porcin
igm
paul
et
al
third
applic
describ
use
isotypespecif
mab
elisa
system
detect
bovin
immunoglobulin
rotaviru
van
zaan
ijzerman
porcin
virusspecif
immunoglobulin
van
zaan
mab
ceu
surfac
marker
also
use
number
area
pinder
et
al
pinder
et
al
demonstr
presenc
bovin
igm
serum
cell
surfac
mab
specif
immunoglobuhn
product
mab
major
histocompatibihti
complex
product
bovin
tissu
type
purpos
attempt
spooner
pinder
littl
success
letteson
et
al
succeed
produc
xenogen
monoclon
antibodi
bovin
tahk
antigen
abihti
distinguish
lymphocyt
use
mab
would
potenti
either
studi
cellular
immun
respons
determin
immun
statu
anim
investig
cattl
lewin
et
al
lewin
et
al
lewin
et
al
swine
lunney
lunney
et
al
differenti
lymphocyt
subpopul
use
mab
report
bovin
cell
rabinowski
yang
porcin
cell
jonjic
koszinowski
potenti
immunotherapeut
applic
mab
wiu
discuss
section
mab
use
develop
immunoassay
detect
toxin
anim
feed
detect
residu
drug
anim
food
product
mab
elisa
system
describ
detect
variou
mycotoxin
includ
anatoxin
candhsh
etal
toxin
ochratoxin
kawamura
et
al
zearalenon
azearalenol
dixon
et
al
previous
mention
anabol
drug
may
employ
growth
promot
anim
anim
feed
may
supplement
antibiot
prophylact
control
infecti
diseas
carter
et
al
prepar
mab
anabol
agent
zeranol
suggest
apphcat
antibodi
immunoassay
monitor
residu
zeranol
anim
product
sever
author
develop
mab
antibiot
suggest
use
immunoassay
detect
presenc
residu
antibiot
anim
product
includ
van
de
water
et
al
use
mab
chloramphenicol
develop
competit
elisa
determin
chloramphenicol
residu
swine
muscl
tissu
pubhcat
applic
mab
poultri
diseas
earli
spite
fact
studi
chicken
immun
system
play
key
role
current
understand
immun
respons
mab
speci
avian
coccidia
first
produc
danforth
augustin
use
immunodiagnost
purpos
report
recent
mab
eimeria
tenella
microgametocyt
employ
hamada
et
al
djilali
parodi
demonstr
blvtransform
sheep
cell
blvspecif
mab
mab
also
use
studi
tumourassoci
antigen
bovin
lymphosarcoma
cell
aida
et
al
mab
contribut
understand
certain
nonvir
infecti
agent
larg
anim
speci
includ
mycoplasma
hyorhini
infect
swine
wise
et
al
chlamydia
psittasi
infect
sheep
delong
mage
detect
streptococcu
agalactia
ainsworth
capley
mycobacterium
bovi
morri
et
al
boothbi
et
al
cattl
knowledg
immun
system
fish
fish
diseas
extrem
limit
compar
knowledg
larg
anim
nevertheless
fish
farm
aquacultur
becom
increasingli
import
food
product
industri
may
play
signific
role
food
sourc
futur
reason
applic
latest
biotechnolog
advanc
includ
mab
aquacultur
industri
extrem
import
fact
occur
addit
applic
industri
area
biotechnolog
beyond
scope
chapter
mab
adopt
purpos
immunoassay
possibl
immunotherapi
see
section
mabbas
elisa
use
studi
vibrio
anguillarum
strain
goerlich
rapid
diagnosi
clinic
case
enter
redmouth
yersinia
ruckeri
furunculosi
aeromona
salmonicida
austin
et
al
fish
farm
mab
also
employ
analysi
lymphocyt
receptor
fiebig
et
al
character
lymphocyt
popul
egbert
et
al
carp
immunopurif
salmon
prolactin
develop
sandwich
elisa
system
salmon
prolactin
somatotropin
furuya
et
al
antiidiotyp
antibodi
anti
antibodi
figur
shown
diagrammat
figur
specif
antigencombin
amino
acid
epitop
sequenc
fold
molecul
hypervari
region
antibodi
anti
e
antibodi
figur
rais
origin
antigen
epitop
e
figur
principl
antiidiotyp
antibodi
use
induc
protect
immun
may
simplifi
follow
way
refer
figur
anim
figur
hyperimmun
antigen
x
produc
antibodi
wide
rang
specif
epitop
x
small
number
antibodi
specif
epitop
anti
e
antibodi
figur
epitopecombin
site
antibodi
contain
mirror
imag
epitop
e
anti
e
antibodi
isol
either
immunoaffin
purif
epitop
immunoadsorb
clone
cell
line
secret
pure
monoclon
anti
e
antibodi
use
hyperimmun
mous
b
figur
amongst
countless
antibodi
specif
produc
epitop
anti
e
antibodi
molecul
small
number
specif
epitop
mirror
imag
origin
epitop
anti
anti
e
antibodi
figur
epitopecombin
site
anti
anti
e
antibodi
mirror
imag
mirror
imag
epitop
e
antigen
ident
origin
epitop
e
anti
anti
e
antibodi
antiidiotyp
antibodi
isol
hybridoma
cell
fusion
clone
procedur
pure
monoclon
antiidiotyp
antibodi
inject
activ
immunogen
anoth
speci
anim
c
figur
anim
produc
proport
antibodi
react
origin
epitop
figur
epitop
viru
involv
viru
neutral
antibodi
may
neutral
viru
figur
antiidiotyp
mab
evalu
immunogen
activ
immun
sever
immunofluoresc
antibodi
techniqu
laxer
et
al
mab
surfac
antigen
eimeria
sporozoit
immunofluoresc
antibodi
test
immunoelectron
microscopi
augustin
danforth
author
apph
mab
diflerenti
strain
avian
leukosi
viru
chicken
differenti
antigen
variant
strain
avian
bronchiti
viru
elisa
koch
et
al
character
antigen
serotyp
isol
marek
diseas
viru
herp
viru
turkey
ikuta
et
al
lee
et
al
hiros
et
al
rapid
diagnosi
infecti
bursal
diseas
avidinperoxidas
stain
cell
smear
chicken
embryo
fibroblast
cultur
bursa
fabriciu
cho
et
al
russel
alexand
studi
antigen
variat
newcastl
diseas
viru
strain
mab
wherea
srinivasappa
et
al
use
mab
specif
vaccin
strain
newcastl
diseas
viru
indirect
elisa
differenti
vaccin
virul
field
strain
van
den
hurk
produc
mab
haemorrhag
enter
viru
hev
turkey
incorpor
antibodi
elisa
quantit
hev
antigen
tissu
extract
assay
sensit
commonli
employ
agar
gel
precipit
test
therefor
use
quantit
hev
antigen
experiment
infect
turkey
principi
antiidiotyp
antibodi
gener
method
use
induc
specif
immun
particular
epitop
group
eg
gurish
et
al
kennedi
et
al
hiernaux
sever
advantag
antiidiotyp
mab
carri
risk
contamin
nucleic
acid
viru
protect
desir
low
toxic
antiidiotyp
mab
mimic
carbohydr
lipid
antigen
determin
epitop
easili
produc
recombin
dna
technolog
nativ
form
may
poorli
immunogen
antiidiotyp
mab
express
fewer
antigen
determin
instanc
bacterin
thu
reduc
chanc
autoimmun
respons
provid
continu
sourc
standard
immunogen
antiidiotyp
mab
also
disadvantag
like
dead
vaccin
rapidli
clear
inject
site
bodi
effect
induc
cellular
immun
differ
speci
establish
antiidiotyp
mab
may
exactli
mimic
origin
epitop
even
singl
epitop
may
induc
protect
immun
final
gener
antiidiotyp
mab
use
antibodi
type
produc
step
extens
test
absorpt
prepar
step
may
necessari
ensur
remov
antispeci
antiallotyp
activ
use
antiidiotyp
mab
induc
protect
immun
infecti
agent
investig
sever
group
reagan
et
al
produc
antiidiotyp
mab
neutral
mab
specif
glycoprotein
g
rabi
viru
immun
mice
anti
idiotyp
mab
result
rabiesneutr
antibodi
respons
stein
sonderstrom
achiev
protect
e
coli
infect
mice
neonat
administr
either
specif
antiidiotyp
idiotyp
antibodi
field
anim
product
variou
antibovin
idiotyp
mab
mimic
epitop
bovin
streptococcu
staphylococcu
strain
describ
arulanandam
et
al
arulanandam
goldsbi
induct
antibodi
cellular
immun
respons
eimeria
tenella
demonstr
chicken
administr
antiidiotyp
mab
bhogal
et
al
success
passiv
protect
anim
virusinduc
diseas
first
report
letchworth
appleton
use
mab
bluetongu
viru
protect
sheep
mice
intraven
challeng
homolog
viru
serotyp
mab
shown
vitro
neutral
viru
inhibit
viru
haemagglutin
precipit
bluetongu
viru
polypeptid
jeggo
et
al
also
describ
partial
protect
sheep
bluetongu
challeng
administr
mab
homolog
viru
serotyp
abil
mab
pseudorabi
glycoprotein
passiv
protect
pig
intranas
challeng
pseudorabi
viru
independ
demonstr
marchioli
et
al
sadowski
et
al
first
report
success
passiv
protect
calv
challeng
enterotoxigen
escherichia
coli
etec
mab
made
sherman
et
al
author
demonstr
mab
produc
varieti
hormon
includ
bovin
progesteron
booman
et
al
bovin
porcin
insuhn
et
al
pregnant
mare
serum
gonadotropin
pmsg
dieleman
et
al
bovin
somatotropin
krivi
rowold
bovin
somatostatin
buchan
et
al
view
success
use
mab
neutral
infecti
agent
vivo
provid
access
mab
bodi
unreason
suggest
hormonespecif
mab
could
potenti
vivo
therapeut
immunomodul
variou
physiolog
function
fact
pmsgspecif
mab
success
fulli
use
dieleman
et
al
modifi
number
ovul
occur
cow
growth
promot
anim
achiev
mani
year
use
variou
anabohc
agent
eg
ralgro
recent
consider
interest
use
growth
hormon
somatotropin
growth
promot
figur
rather
extract
hormon
pituitari
gland
gene
porcin
somatotropin
pst
bovin
somatotropin
bst
clone
express
bacteria
genet
engin
hormon
produc
larg
quantiti
use
ferment
cultur
summer
sever
compani
made
major
invest
technolog
ingenthron
simkin
eggert
summer
extens
studi
effect
recombin
pst
growth
rate
pig
recombin
bst
milk
product
dairi
cattl
current
underway
pitmanmoor
american
cyanamid
respect
summer
simkin
eggert
use
somatotropin
increas
anim
product
disadvantag
howev
due
put
speciesspecif
effect
summer
possibiuti
residu
recombin
materi
meat
dairi
product
lister
altern
approach
growth
promot
use
antibodi
somatostatin
figur
neutral
somatostatin
result
net
increas
level
nativ
somatotropin
produc
pituitari
gland
activ
immun
sheep
somatostatin
conjug
shown
effect
produc
signific
increas
weight
gain
improv
food
util
effici
spencer
wherea
activ
immun
lactat
goat
significantli
increas
milk
product
spencer
garssen
et
al
activ
immun
somatostatin
sever
problem
howev
includ
low
immunogen
somatostatin
due
natur
occur
hormon
recogn
self
immun
system
variabl
somatostatinspecif
immun
respons
individu
anim
differ
anim
speci
spencer
passiv
immun
somatostatin
suggest
altern
approach
growth
promot
spencer
shown
effect
use
somatostatinspecif
goat
antiserum
buonomo
et
al
polyclon
antibodi
somatostatin
also
use
plisetskaya
et
al
investig
effect
vivo
insuun
glucagon
level
coho
salmon
somatostatinspecif
mab
produc
bind
somatostatin
demonstr
vitro
buchan
et
al
vivo
seal
et
al
though
public
efficaci
mab
growth
promotor
appear
scientif
hteratur
report
indic
oral
administr
ascit
fluid
contain
mab
specif
fimbria
pilu
antigen
involv
adhes
etec
cell
gut
wall
colon
etec
prevent
death
reduc
chnical
symptom
result
oral
challeng
etec
sadowski
et
al
demonstr
similar
protect
abil
fimbria
pilu
specif
mab
reduc
mortal
due
etec
induc
colibacillosi
neonat
pig
foge
et
al
suggest
fimbria
pilu
specif
mab
might
also
protect
posit
etec
support
experiment
data
includ
paper
possibl
use
mab
passiv
protect
neonat
calv
anoth
import
diarrhoeacaus
agent
investig
thiriart
et
al
author
attempt
protect
neonat
calv
experiment
infect
bovin
rotaviru
oral
administr
rotavirusspecif
mab
unfortun
though
mab
individu
neutral
homolog
ou
bovin
rotaviru
vitro
protect
vivo
even
combin
differ
mab
use
failur
mab
provid
passiv
protect
rotaviru
challeng
like
due
differ
pathogenesi
etec
rotavirusinduc
diarrhoea
fimbria
pilu
specif
mab
probabl
protect
bind
fimbria
etec
cell
involv
adhes
etec
epitheli
cell
small
intestin
thu
prevent
adhes
subsequ
colon
rotaviru
howev
infect
intestin
villou
epitheli
cell
cell
entri
occur
viru
may
longer
access
neutral
mab
may
equal
effect
recombin
somatotropin
without
disadvantag
maccecchini
marberi
mab
produc
rang
surfac
marker
immun
cell
anim
pinder
et
al
pinder
et
al
letteson
et
al
spooner
pinder
jonjic
koszinowski
lewin
et
al
lewin
et
al
lunney
lunney
et
al
rabinowski
yang
lewin
et
al
mab
togeth
other
suitabl
specif
might
usabl
vivo
reduc
number
select
type
immun
cell
select
deplet
achiev
im
munomodul
varieti
immunolog
disord
diseas
state
certain
group
fact
investig
potenti
applic
mab
area
pavlov
et
al
steplowski
et
al
green
et
al
steel
et
al
select
deplet
cell
popul
use
suitabl
mab
might
apphcat
variou
lymphoprohf
diseas
anim
field
human
medicin
mab
tumour
cell
surfac
marker
use
aid
diagnosi
monitor
diseas
progress
addit
immunotherapi
excel
review
pubhsh
applic
mab
manag
human
tumour
abram
oldham
woolfenden
larson
houghton
scheinberg
schlom
mani
use
may
applic
veterinari
medicin
cost
effect
mab
therapi
immunomodul
tumour
manag
determin
extent
use
improv
health
product
foodproduc
anim
one
problem
associ
use
murin
mab
immunotherapi
nonmurin
anim
speci
develop
immun
treat
anim
murin
mab
case
repeat
inject
prolong
mab
therapi
hkeli
antibodi
produc
treat
anim
murin
mab
neutrahz
mab
exert
desir
effect
mab
use
therapeut
purpos
cooper
antibodi
cell
complement
accessori
immunolog
defenc
mechan
import
therapi
technolog
mab
product
exist
year
yet
applic
anim
health
product
clearli
still
infanc
advanc
human
medicin
usual
result
new
technolog
develop
anim
model
use
mab
anim
health
revers
may
true
particularli
therapeut
applic
human
medic
research
may
provid
clue
futur
mab
applic
anim
health
recent
advanc
hybridoma
technolog
abil
gener
speci
mab
improv
vitro
product
method
expand
use
even
chapter
consid
mani
use
mab
improv
health
product
foodproduc
anim
shown
versatil
suggest
futur
valu
chapter
began
stress
busi
aspect
anim
health
product
industri
end
sentiment
true
valu
mab
applic
anim
health
product
realiz
technolog
product
variou
use
reach
point
produc
truli
cost
effect
method
improv
profit
may
effect
mab
speci
anim
treatment
use
one
method
overcom
first
problem
use
tolerogen
poli
ethylen
glycol
deriv
xenogen
mab
wilkinson
et
al
anoth
approach
address
problem
use
mab
speci
anim
treatment
product
bovin
mab
bovinemurin
hybridoma
first
report
srikumaran
et
al
srikumaran
et
al
unfortun
bovin
monoclon
immunoglobuun
unknown
specif
tucker
et
al
refus
bovinemurin
hybridoma
obtain
hne
secret
bovin
mab
author
conclud
probabl
direct
forssman
antigen
sheep
erythrocyt
data
confirm
specif
howev
present
raybould
et
al
publish
first
report
describ
product
bovin
mab
defin
specif
infecti
agent
author
produc
bovinemurin
hybridoma
secret
bovin
iggj
specif
kda
structur
polypeptid
bovin
enter
coronaviru
year
goldsbi
et
al
describ
bovinemurin
hybridoma
secret
bovin
mab
staphylococcu
aureu
escherichia
coli
streptococcu
agalactia
raybould
et
al
report
product
porcinemurin
hybridoma
secret
porcin
monoclon
igg
kda
polypeptid
enterotoxigen
escherichia
coli
sheepmous
hybridoma
origin
produc
tucker
et
al
hybridoma
fail
secret
mab
howev
grove
et
al
report
success
product
stabl
sheepmous
hybridoma
secret
sheep
mab
testosteron
product
bovin
mab
potenti
immunotherapeut
use
achiev
anderson
et
al
refus
bovinemurin
hybridoma
obtain
stabl
line
secret
bovin
mab
fimbria
pili
etec
comparison
efficaci
bovin
mab
murin
mab
describ
sherman
et
al
passiv
protect
calv
etec
challeng
would
valuabl
experi
